Emphasizing restriction spectrum imaging (RSI), the recently launched prostate MRI software OnQ Prostate may enhance PI-RADS assessments and workflow efficiency.
In order to enhance the detection of clinically significant prostate cancer (csPCa), Cortechs.ai has launched OnQ Prostate, a post-processing software that may bolster prostate MRI interpretation through a proprietary diffusion-weighted imaging called restriction spectrum imaging (RSI).
Originally developed for brain cancer imaging, RSI reportedly increases the detection of aggressive cancer cells, according to Cortechs.ai. The company noted that research with the FDA-cleared OnQ Prostate software has demonstrated improved in vivo characterization and localization of csPCa on diffusion MRI imaging.
In addition to improved accuracy with PI-RADS assessments, Cortechs.ai said the OnQ Prostate software offers a versatility that can enhance workflows with radiologists and referring providers by facilitating patient selection for biopsy procedures, treatment planning and post-treatment assessment.
“This announcement is an important step in increasing the awareness and accessibility of OnQ Prostate beyond its earliest adopters so that more physicians and patients can benefit from this technology,” says Brittany Hunt, the head of prostate business development at Cortechs.ai.
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.